Product Name: AurB (319-333)
Product Number: PE-01AWX85
| Size: | 200 µg | Price: | 38.00 | |
| 1 mg | $US | 77.00 | ||
| 5 mg | 166.00 |
Peptide Name: AurB (319-333)
Product Use: Services as a blocking peptide for use with the AurKB-3 rabbit polyclonal antibody (Cat. No.: AB-NK193-4) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CAQVSAHPWVRANSRR
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1837.09 Da
Peptide Purity Percent after Synthesis and Purification: >80
Product Use: Services as a blocking peptide for use with the AurKB-3 rabbit polyclonal antibody (Cat. No.: AB-NK193-4) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CAQVSAHPWVRANSRR
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1837.09 Da
Peptide Purity Percent after Synthesis and Purification: >80
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: AurB pan-specific antibody (Cat. No.: AB-NK193-4)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: AurB pan-specific antibody (Cat. No.: AB-NK193-4)
Scientific Background: AurB (AurKB, AIK2) is a protein-serine/threonine kinase of the Other group and AUR family. It serves as a component of the chromosomal passenger complex (CPC) that plays a critical role in regulating mitosis. AurB may be a tumour requiring protein (TRP). Its low rate of mutation and down-regulation in human cancers supports it identification as a tumour-requiring protein, and as a target for cancer drug development. However, AurB is overexpressed in some colorectal cancers and other tumour cell lines, which was thought to lead to multinuclearity, increased ploidy, and a predisposition to cancer. Through its dominant-negative effect on cytokinesis, disruptive regulation of its expression is potentially responsible for the perturbing the chromosomal integrity in cancer cells. A K106R mutation leads to loss of phosphotransferase activity, and severely impairs mitosis.
© Kinexus Bioinformatics Corporation 2017